Warning letter
Paramesh Banerji Life Sciences, LLC: warning letter of Aug 7, 2018
FDA warning letter 547958 · New Jersey District Office
Key facts
| Reference number | 547958 |
|---|---|
| Company | Paramesh Banerji Life Sciences, LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Aug 7, 2018 |
| Posted date | Aug 14, 2018 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.110, 211.22(a), 211.84(d)(1), 211.100(a), 211.160(b) |
| Inspection city | North Brunswick |
| Inspection ZIP | 08902 |
| Inspection start date | Nov 28, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: